Trials / Completed
CompletedNCT02206867
Pharmacokinetics and Safety Study of LBAL in Healthy Subjects
A Randomized, Double-Blind, Parallel-Group Clinical Study to Compare Pharmacokinetics, Safety and Tolerability of LBAL 40 mg With Humira® 40 mg After a Single Subcutaneous Administration in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- LG Life Sciences · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To compare PK, safety and tolerability of LBAL developed by LG Life Sciences Ltd. With those of Humira®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LBAL | Anti-inflammatory agents |
| BIOLOGICAL | Humira | Anti-inflammatory agents |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2014-08-01
- Last updated
- 2015-06-15
Source: ClinicalTrials.gov record NCT02206867. Inclusion in this directory is not an endorsement.